No Overall Survival Benefit With Bevacizumab for Ovarian Cancer

June 28, 2019 9:34 AM | Grant Dvorak (Administrator)

June 28, 2019, Medpage Today 

The final analysis of a major trial in advanced ovarian cancer continued to show no survival improvement with the addition of bevacizumab (Avastin) to chemotherapy, 9 years after the initial analysis showed no survival benefit.

Read more.


Powered by Wild Apricot Membership Software